Publications
Found 1 results
Filters: Author is D.B. Li [Clear All Filters]
“Meta-analysis of epidemiological studies of association of P53 codon 72 polymorphism with bladder cancer”, vol. 9, pp. 1599-1605, 2010.
, Begg CB and Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
http://dx.doi.org/10.2307/2533446
PMid:7786990
Chen WC, Tsai FJ, Wu JY, Wu HC, et al. (2000). Distributions of p53 codon 72 polymorphism in bladder cancer-proline form is prominent in invasive tumor. Urol. Res. 28: 293-296.
http://dx.doi.org/10.1007/s002400000117
PMid:11127705
Dai S, Mao C, Jiang L, Wang G, et al. (2009). p53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum. Genet. 125: 633-638.
http://dx.doi.org/10.1007/s00439-009-0664-3
PMid:19357867
Egger M, Davey SG, Schneider M and Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
http://dx.doi.org/10.1136/bmj.315.7109.629
PMid:9310563 PMCid:2127453
Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991). p53 mutations in human cancers. Science 253: 49-53.
http://dx.doi.org/10.1126/science.1905840
PMid:1905840
Horikawa Y, Nadaoka J, Saito M, Kumazawa T, et al. (2008). Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol. Rep. 20: 49-55.
PMid:18575717
Ioannidis JP, Boffetta P, Little J, O'Brien TR, et al. (2008). Assessment of cumulative evidence on genetic associations: interim guidelines. Int. J. Epidemiol. 37: 120-132.
http://dx.doi.org/10.1093/ije/dym159
PMid:17898028
Jemal A, Siegel R, Ward E, Hao Y, et al. (2008). Cancer statistics, 2008. CA Cancer J. Clin. 58: 71-96.
http://dx.doi.org/10.3322/CA.2007.0010
PMid:18287387
Kaufman DS, Shipley WU and Feldman AS (2009). Bladder cancer. Lancet 374: 239-249.
http://dx.doi.org/10.1016/S0140-6736(09)60491-8
Klug SJ, Ressing M, Koenig J, Abba MC, et al. (2009). TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 10: 772-784.
http://dx.doi.org/10.1016/S1470-2045(09)70187-1
Koushik A, Tranah GJ, Ma J, Stampfer MJ, et al. (2006). p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int. J. Cancer 119: 1863-1868.
http://dx.doi.org/10.1002/ijc.22057
PMid:16721787
Lee JM, Shun CT, Wu MT, Chen YY, et al. (2006). The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat. Res. 594: 181-188.
http://dx.doi.org/10.1016/j.mrfmmm.2005.09.003
PMid:16318864
Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
http://dx.doi.org/10.1016/S0092-8674(00)81871-1
Lopez-Beltran A, Escudero AL, Vicioso L, Munoz E, et al. (1996). Human papillomavirus DNA as a factor determining the survival of bladder cancer patients. Br. J. Cancer 73: 124-127.
http://dx.doi.org/10.1038/bjc.1996.23
PMid:8554974 PMCid:2074275
Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, et al. (2003). No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann. N. Y. Acad. Sci. 1010: 764-770.
http://dx.doi.org/10.1196/annals.1299.137
PMid:15033824
Maloney KE, Wiener JS and Walther PJ (1994). Oncogenic human papillomaviruses are rarely associated with squamous cell carcinoma of the bladder: evaluation by differential polymerase chain reaction. J. Urol. 151: 360-364.
PMid:8283525
Matakidou A, Eisen T and Houlston RS (2003). TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 18: 377-385.
http://dx.doi.org/10.1093/mutage/geg008
PMid:12840112
Murgel de Castro Santos LE, Trindade Guilhen AC, Alves de AR, Garcia SL, et al. (2009). The role of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms in the susceptibility to bladder cancer. Urol. Oncol. (in press). DOI: 10.1016/j.urolonc.2009.03.026.
http://dx.doi.org/10.1016/j.urolonc.2009.03.026
Rubben H, Lutzeyer W, Fischer N, Deutz F, et al. (1988). Natural history and treatment of low and high risk superficial bladder tumors. J. Urol. 139: 283-285.
PMid:3339726
Simoneau M, LaRue H and Fradet Y (1999). Low frequency of human papillomavirus infection in initial papillary bladder tumors. Urol. Res. 27: 180-184.
http://dx.doi.org/10.1007/s002400050107
PMid:10422819
Soulitzis N, Sourvinos G, Dokianakis DN and Spandidos DA (2002). p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 179: 175-183.
http://dx.doi.org/10.1016/S0304-3835(01)00867-9
Sousa H, Santos AM, Pinto D and Medeiros R (2007). Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int. J. Mol. Med. 20: 731-741.
PMid:17912468
Tommiska J, Eerola H, Heinonen M, Salonen L, et al. (2005). Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin. Cancer Res. 11: 5098-5103.
http://dx.doi.org/10.1158/1078-0432.CCR-05-0173
PMid:16033823
Toruner GA, Ucar A, Tez M, Cetinkaya M, et al. (2001). p53 codon 72 polymorphism in bladder cancer - no evidence of association with increased risk or invasiveness. Urol. Res. 29: 393-395.
http://dx.doi.org/10.1007/s002400100218
PMid:11828992
Zhou Y, Li N, Zhuang W, Liu GJ, et al. (2007). p53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int. J. Cancer 121: 1481-1486.
http://dx.doi.org/10.1002/ijc.22833
PMid:17546594